All news

A director proposes selling 1,209 Ligand Pharmaceuticals (LGND) shares around October 30, 2026.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Ligand Pharmaceuticals Inc. director Jason M. Aryeh has proposed selling 1,209 common shares of the company, valued at approximately $385,185.47, with an anticipated sale date of October 30, 2026. These shares are identified as restricted stock, which he acquired from Ligand Pharmaceuticals Inc. on June 5, 2026.

Read original source

LGND company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.